



## Clinical trial results:

### A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)

#### Summary

|                          |                         |
|--------------------------|-------------------------|
| EudraCT number           | 2020-005303-39          |
| Trial protocol           | ES DE SK NL CZ PL GR IT |
| Global end of trial date | 04 August 2023          |

#### Results information

|                                |                |
|--------------------------------|----------------|
| Result version number          | v1             |
| This version publication date  | 11 August 2024 |
| First version publication date | 11 August 2024 |

#### Trial information

##### Trial identification

|                       |         |
|-----------------------|---------|
| Sponsor protocol code | M20-466 |
|-----------------------|---------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04888585 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | AbbVie Deutschland GmbH & Co. KG  |
| Sponsor organisation address | AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6 4UB                                     |
| Public contact               | Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a> |
| Scientific contact           | Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a> |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                |
|--|----------------|
| Analysis stage                                       | Final          |
| Date of interim/final analysis                       | 04 August 2023 |
| Is this the analysis of the primary completion data? | No             |
| Global end of trial reached?                         | Yes            |
| Global end of trial date                             | 04 August 2023 |
| Was the trial ended prematurely?                     | Yes            |

Notes:

## General information about the trial

Main objective of the trial:

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study aimed to evaluate how safe and effective ABBV-154 is in subjects treated for moderately to severely active RA. Adverse events and change in the disease activity were assessed.

ABBV-154 is an investigational drug being evaluated for the treatment of RA. Approximately 425 subjects 18-75 years of age with moderate to severe RA were enrolled in the study at approximately 270 sites worldwide. Subjects attended regular visits during the study at a hospital or clinic. The effect of the treatment was checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Protection of trial subjects:

Subjects read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

|   |              |
|---|--------------|
| Actual start date of recruitment                          | 23 June 2021 |
| Long term follow-up planned                               | No           |
| Independent data monitoring committee (IDMC) involvement? | Yes          |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                       |
|--------------------------------------|-----------------------|
| Country: Number of subjects enrolled | Canada: 4             |
| Country: Number of subjects enrolled | Germany: 15           |
| Country: Number of subjects enrolled | Greece: 3             |
| Country: Number of subjects enrolled | Hungary: 42           |
| Country: Number of subjects enrolled | Israel: 12            |
| Country: Number of subjects enrolled | Italy: 5              |
| Country: Number of subjects enrolled | Japan: 66             |
| Country: Number of subjects enrolled | Poland: 22            |
| Country: Number of subjects enrolled | Puerto Rico: 8        |
| Country: Number of subjects enrolled | Russian Federation: 6 |
| Country: Number of subjects enrolled | Slovakia: 13          |
| Country: Number of subjects enrolled | Spain: 19             |
| Country: Number of subjects enrolled | Taiwan: 1             |

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United States: 232 |
| Country: Number of subjects enrolled | Czechia: 25        |
| Worldwide total number of subjects   | 473                |
| EEA total number of subjects         | 144                |

Notes:

| <b>Subjects enrolled per age group</b>    |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 337 |
| From 65 to 84 years                       | 136 |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

A total of 473 participants (All Randomized Population) were enrolled in the study. The ITT Population (N=472) included all participants who were randomized and received at least 1 dose of study drug. One randomized participant was not treated and thus not included in the ITT Population.

### Pre-assignment

Screening details:

After a 12 week placebo-controlled period, subjects in the Placebo group were re-randomized to ABBV-154 at 2 different doses SC every other week, while others remained on their previous dose. There was a planned double-blind long term extension (LTE) of 66 weeks and a LTE 2 of 104 weeks. The study was terminated before any subjects entered LTE 2.

### Period 1

|                              |                           |
|------------------------------|---------------------------|
| Period 1 title               | Placebo-Controlled Period |
| Is this the baseline period? | Yes                       |
| Allocation method            | Randomised - controlled   |
| Blinding used                | Double blind              |
| Roles blinded                | Subject, Investigator     |

Blinding implementation details:

Subjects were randomized to 5 treatment groups in a 1:1:1:1:1 ratio to receive blinded ABBV-154 at a dose of 40 mg, 150 mg, or 340 mg, subcutaneously (SC) every other week (EOW); 340 mg SC E4W; or placebo SC EOW for 12 weeks.

### Arms

|                              |  |
|------------------------------|--|
| Are arms mutually exclusive? | Yes  |
| <b>Arm title</b>             | Period 1 (Placebo-Controlled Period) Placebo |

Arm description:

Subjects in this group received placebo subcutaneously (SC) every other week (EOW) for 12 weeks in the placebo-controlled period and were re-randomized at 1:1 ratio to receive ABBV-154 150 mg or 340 mg SC EOW for 66 weeks in the long term extension (LTE) period.

|  |   |
|--|---|
| Arm type                               | Placebo   |
| Investigational medicinal product name | Placebo   |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration               | Subcutaneous use                                      |

Dosage and administration details:

Subcutaneous injection

|                  |   |
|------------------|---|
| <b>Arm title</b> | Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
|------------------|---|

Arm description:

Subjects in this group received 40 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|  |   |
|--|---|
| Arm type                               | Active comparator                                     |
| Investigational medicinal product name | ABBV-154  |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration               | Subcutaneous use                                      |

Dosage and administration details:

Subcutaneous Injection

|   |  |
|---|--|
| <b>Arm title</b>  | Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Arm description:<br>Subjects in this group received 150 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period. One randomized subject in this arm was ineligible and did not receive treatment. This subject was not included in the ITT population. |  |
| Arm type  | Active comparator  |
| Investigational medicinal product name  | ABBV-154   |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection/infusion in pre-filled syringe    |
| Routes of administration  | Subcutaneous use   |

Dosage and administration details:

Subcutaneous Injection

|   |  |
|---|--|
| <b>Arm title</b>  | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Arm description:<br>Subjects in this group received 340 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period. |  |
| Arm type  | Active comparator  |
| Investigational medicinal product name  | ABBV-154   |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection/infusion in pre-filled syringe    |
| Routes of administration  | Subcutaneous use   |

Dosage and administration details:

Subcutaneous Injection

|   |  |
|---|--|
| <b>Arm title</b>  | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Arm description:<br>Subjects in this group received 340 mg of ABBV-154 SC every 4 weeks (E4W) for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period. |  |
| Arm type  | Active comparator  |
| Investigational medicinal product name  | ABBV-154   |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Solution for injection/infusion in pre-filled syringe    |
| Routes of administration  | Subcutaneous use   |

Dosage and administration details:

Subcutaneous Injection

| Number of subjects in period 1 <sup>[1]</sup> | Period 1 (Placebo-Controlled Period) Placebo | Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW | Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
|---|--|---|--|
|   |  |   |  |
| Started                                       | 96   | 98  | 94   |
| Completed                                     | 92   | 93  | 86   |
| Not completed                                 | 4  | 5   | 8  |
| Consent withdrawn by subject                  | -  | 1   | 4  |

|                   |   |   |   |
|-------------------|---|---|---|
| Other             | 4 | 4 | 3 |
| Lost to follow-up | - | - | 1 |

| <b>Number of subjects in period 1<sup>[1]</sup></b> | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
|---|--|--|
| Started   | 90   | 94   |
| Completed   | 85   | 89   |
| Not completed                                       | 5  | 5  |
| Consent withdrawn by subject                        | 3  | 3  |
| Other   | 2  | 1  |
| Lost to follow-up                                   | -  | 1  |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One randomized subject was ineligible and did not receive treatment. This subject was not included in the ITT population.

## Period 2

|                              |                            |
|------------------------------|----------------------------|
| Period 2 title               | Long-Term Extension Period |
| Is this the baseline period? | No                         |
| Allocation method            | Randomised - controlled    |
| Blinding used                | Double blind               |
| Roles blinded                | Subject, Investigator      |

## Arms

|                              |  |
|------------------------------|--|
| Are arms mutually exclusive? | Yes  |
| <b>Arm title</b>             | Period 2 (Extension Period) Placebo to ABBV-154 150 mg EOW |

Arm description:

Subjects in this group received placebo subcutaneously (SC) every other week (EOW) for 12 weeks in the placebo-controlled period and were re-randomized in 1:1 ratio to receive ABBV-154 150 mg or 340 mg respectively SC EOW for 66 weeks in the long term extension (LTE) period.

|  |   |
|--|---|
| Arm type                               | Active comparator                                     |
| Investigational medicinal product name | ABBV-154  |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration               | Subcutaneous use                                      |

Dosage and administration details:

Subcutaneous Injection

|                  |  |
|------------------|--|
| <b>Arm title</b> | Period 2 (Extension Period) Placebo to ABBV-154 340 mg EOW |
|------------------|--|

Arm description:

Subjects in this group received placebo SC EOW for 12 weeks in the placebo-controlled period and were re-randomized in 1:1 ratio to receive ABBV-154 150 mg or 340 mg respectively SC EOW for 66 weeks in the LTE period.

|          |                   |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

|  |   |
|--|---|
| Investigational medicinal product name                       | ABBV-154  |
| Investigational medicinal product code                       |   |
| Other name   |   |
| Pharmaceutical forms   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration                                     | Subcutaneous use                                      |
| Dosage and administration details:<br>Subcutaneous Injection |   |

|                  |  |
|------------------|--|
| <b>Arm title</b> | Period 2 (Extension Period) ABBV-154 40 mg EOW |
|------------------|--|

Arm description:

Subjects in this group received 40 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|  |   |
|--|---|
| Arm type                               | Active comparator                                     |
| Investigational medicinal product name | ABBV-154  |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration               | Subcutaneous use                                      |

Dosage and administration details:

Subcutaneous Injection

|                  |   |
|------------------|---|
| <b>Arm title</b> | Period 2 (Extension Period) ABBV-154 150 mg EOW |
|------------------|---|

Arm description:

Subjects in this group received 150 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|  |   |
|--|---|
| Arm type                               | Active comparator                                     |
| Investigational medicinal product name | ABBV-154  |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration               | Subcutaneous use                                      |

Dosage and administration details:

Subcutaneous Injection

|                  |   |
|------------------|---|
| <b>Arm title</b> | Period 2 (Extension Period) ABBV-154 340 mg EOW |
|------------------|---|

Arm description:

Subjects in this group received 340 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|  |   |
|--|---|
| Arm type                               | Active comparator                                     |
| Investigational medicinal product name | ABBV-154  |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration               | Subcutaneous use                                      |

Dosage and administration details:

Subcutaneous Injection

|                  |   |
|------------------|---|
| <b>Arm title</b> | Period 2 (Extension Period) ABBV-154 340 mg E4W |
|------------------|---|

Arm description:

Subjects in this group received 340 mg of ABBV-154 SC every 4 weeks (E4W) for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|          |                   |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

|  |   |
|--|---|
| Investigational medicinal product name | ABBV-154  |
| Investigational medicinal product code |   |
| Other name                             |   |
| Pharmaceutical forms                   | Solution for injection/infusion in pre-filled syringe |
| Routes of administration               | Subcutaneous use                                      |
| Dosage and administration details:     |   |
| Subcutaneous Injection                 |   |

| <b>Number of subjects in period 2<sup>[2]</sup></b> | Period 2 (Extension Period) Placebo to ABBV-154 150 mg EOW | Period 2 (Extension Period) Placebo to ABBV-154 340 mg EOW | Period 2 (Extension Period) ABBV-154 40 mg EOW |
|---|--|--|--|
| Started   | 45   | 46   | 93   |
| Completed   | 0  | 0  | 0  |
| Not completed                                       | 45   | 46   | 93   |
| Consent withdrawn by subject                        | 5  | 5  | 8  |
| Other   | 3  | 1  | 4  |
| Death   | -  | -  | 1  |
| Study terminated by sponsor                         | 37   | 36   | 78   |
| Lost to follow-up                                   | -  | 4  | 2  |

| <b>Number of subjects in period 2<sup>[2]</sup></b> | Period 2 (Extension Period) ABBV-154 150 mg EOW | Period 2 (Extension Period) ABBV-154 340 mg EOW | Period 2 (Extension Period) ABBV-154 340 mg E4W |
|---|---|---|---|
| Started   | 86  | 85  | 89  |
| Completed   | 0   | 0   | 0   |
| Not completed                                       | 86  | 85  | 89  |
| Consent withdrawn by subject                        | 8   | 8   | 11  |
| Other   | 5   | 5   | 3   |
| Death   | -   | -   | 3   |
| Study terminated by sponsor                         | 71  | 71  | 72  |
| Lost to follow-up                                   | 2   | 1   | -   |

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: One subject from Period 1 Placebo group did not enter Period 2.



## Baseline characteristics

### Reporting groups

|   |  |
|---|--|
| Reporting group title   | Period 1 (Placebo-Controlled Period) Placebo             |
| Reporting group description:<br>Subjects in this group received placebo subcutaneously (SC) every other week (EOW) for 12 weeks in the placebo-controlled period and were re-randomized at 1:1 ratio to receive ABBV-154 150 mg or 340 mg SC EOW for 66 weeks in the long term extension (LTE) period.        |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW  |
| Reporting group description:<br>Subjects in this group received 40 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.  |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Reporting group description:<br>Subjects in this group received 150 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period. One randomized subject in this arm was ineligible and did not receive treatment. This subject was not included in the ITT population. |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Reporting group description:<br>Subjects in this group received 340 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.   |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Reporting group description:<br>Subjects in this group received 340 mg of ABBV-154 SC every 4 weeks (E4W) for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.   |  |

| Reporting group values                | Period 1 (Placebo-Controlled Period) Placebo | Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW | Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
|---------------------------------------|--|---|--|
| Number of subjects                    | 96   | 98  | 94   |
| Age categorical<br>Units: Subjects    |  |   |  |
| < 40                                  | 6  | 7   | 5  |
| 40–65                                 | 60   | 68  | 65   |
| >=65                                  | 30   | 23  | 24   |
| Age continuous<br>Units: years        |  |   |  |
| arithmetic mean                       | 57.8   | 56.2  | 56.8   |
| standard deviation                    | ± 11.28                                      | ± 10.17   | ± 9.91   |
| Gender categorical<br>Units: Subjects |  |   |  |
| Female                                | 80   | 76  | 73   |
| Male                                  | 16   | 22  | 21   |

| Reporting group values | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W | Total |
|------------------------|--|--|-------|
| Number of subjects     | 90   | 94   | 472   |

|                                       |         |         |     |
|---------------------------------------|---------|---------|-----|
| Age categorical<br>Units: Subjects    |         |         |     |
| < 40                                  | 6       | 9       | 33  |
| 40–65                                 | 55      | 55      | 303 |
| >=65                                  | 29      | 30      | 136 |
| Age continuous<br>Units: years        |         |         |     |
| arithmetic mean                       | 59.5    | 57.9    |     |
| standard deviation                    | ± 10.72 | ± 10.70 | -   |
| Gender categorical<br>Units: Subjects |         |         |     |
| Female                                | 70      | 74      | 373 |
| Male                                  | 20      | 20      | 99  |

## End points

### End points reporting groups

|   |  |
|---|--|
| Reporting group title   | Period 1 (Placebo-Controlled Period) Placebo               |
| Reporting group description:<br>Subjects in this group received placebo subcutaneously (SC) every other week (EOW) for 12 weeks in the placebo-controlled period and were re-randomized at 1:1 ratio to receive ABBV-154 150 mg or 340 mg SC EOW for 66 weeks in the long term extension (LTE) period.              |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW    |
| Reporting group description:<br>Subjects in this group received 40 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.  |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW   |
| Reporting group description:<br>Subjects in this group received 150 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period. One randomized subject in this arm was ineligible and did not receive treatment. This subject was not included in the ITT population.       |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW   |
| Reporting group description:<br>Subjects in this group received 340 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.   |  |
| Reporting group title   | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W   |
| Reporting group description:<br>Subjects in this group received 340 mg of ABBV-154 SC every 4 weeks (E4W) for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.   |  |
| Reporting group title   | Period 2 (Extension Period) Placebo to ABBV-154 150 mg EOW |
| Reporting group description:<br>Subjects in this group received placebo subcutaneously (SC) every other week (EOW) for 12 weeks in the placebo-controlled period and were re-randomized in 1:1 ratio to receive ABBV-154 150 mg or 340 mg respectively SC EOW for 66 weeks in the long term extension (LTE) period. |  |
| Reporting group title   | Period 2 (Extension Period) Placebo to ABBV-154 340 mg EOW |
| Reporting group description:<br>Subjects in this group received placebo SC EOW for 12 weeks in the placebo-controlled period and were re-randomized in 1:1 ratio to receive ABBV-154 150 mg or 340 mg respectively SC EOW for 66 weeks in the LTE period.   |  |
| Reporting group title   | Period 2 (Extension Period) ABBV-154 40 mg EOW             |
| Reporting group description:<br>Subjects in this group received 40 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.  |  |
| Reporting group title   | Period 2 (Extension Period) ABBV-154 150 mg EOW            |
| Reporting group description:<br>Subjects in this group received 150 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.   |  |
| Reporting group title   | Period 2 (Extension Period) ABBV-154 340 mg EOW            |
| Reporting group description:<br>Subjects in this group received 340 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.   |  |
| Reporting group title   | Period 2 (Extension Period) ABBV-154 340 mg E4W            |
| Reporting group description:<br>Subjects in this group received 340 mg of ABBV-154 SC every 4 weeks (E4W) for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.   |  |

**Primary: Achievement of 50% Improvement as Measured by American College of Rheumatology Response Criteria (ACR50) at Week 12**

|                 |   |
|-----------------|---|
| End point title | Achievement of 50% Improvement as Measured by American College of Rheumatology Response Criteria (ACR50) at Week 12 |
|-----------------|---|

## End point description:

Subjects who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria:

- ≥ 50% improvement in 68-tender joint count;
- ≥ 50% improvement in 66-swollen joint count; and
- ≥ 50% improvement in at least 3 of the 5 following parameters:
  - Physician's Global Assessment of Disease Activity (NRS)
  - Patient's Global Assessment of Disease Activity (NRS)
  - Patient's Assessment of Pain (NRS)
  - Health Assessment Questionnaire - Disability Index (HAQ-DI)
  - High-sensitivity C-reactive protein (hsCRP).

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

## End point timeframe:

Week 12

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|----------------------------------|--|--|---|---|
| Subject group type               | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed      | 96 <sup>[1]</sup>                                      | 98 <sup>[2]</sup>  | 94 <sup>[3]</sup>   | 90 <sup>[4]</sup>   |
| Units: percentage of subjects    |  |  |   |   |
| number (confidence interval 95%) | 6.3 (1.4 to 11.1)                                      | 25.5 (16.9 to 34.1)  | 33.3 (23.7 to 42.9)   | 44.4 (34.2 to 54.7)   |

## Notes:

[1] - ITT analysis set subjects were included (N=472)

[2] - ITT analysis set subjects were included (N=472)

[3] - ITT analysis set subjects were included (N=472)

[4] - ITT analysis set subjects were included (N=472)

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|----------------------------------|---|--|--|--|
| Subject group type               | Reporting group   |  |  |  |
| Number of subjects analysed      | 94 <sup>[5]</sup>   |  |  |  |
| Units: percentage of subjects    |   |  |  |  |
| number (confidence interval 95%) | 30.9 (21.5 to 40.2)   |  |  |  |

## Notes:

[5] - ITT analysis set subjects were included (N=472)

**Statistical analyses**

|                            |   |
|----------------------------|---|
| Statistical analysis title | Statistical Analysis 1                                  |
| Comparison groups          | Period 1 (Placebo-Controlled Period) Placebo v Period 1 |

|   |  |
|---|--|
|   | (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 194  |
| Analysis specification                  | Pre-specified                                  |
| Analysis type                           | superiority                                    |
| P-value                                 | < 0.001 <sup>[6]</sup>                         |
| Method                                  | Cochran-Mantel-Haenszel                        |
| Parameter estimate                      | Response Rate Difference                       |
| Point estimate                          | 21.2   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 11.5   |
| upper limit                             | 31   |

Notes:

[6] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[7]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 26.6  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 16.5  |
| upper limit                             | 36.7  |

Notes:

[7] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 3  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Number of subjects included in analysis | 186   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[8]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 37.7  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 27.4  |
| upper limit                             | 48.1  |

Notes:

[8] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 4  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[9]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 23.2  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 13.8  |
| upper limit                             | 32.6  |

Notes:

[9] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

## Secondary: Change From Baseline in Disease Activity Score (DAS) 28 (CRP) at Week 12

|                 |  |
|-----------------|--|
| End point title | Change From Baseline in Disease Activity Score (DAS) 28 (CRP) at Week 12 |
|-----------------|--|

End point description:

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline to Week 12

| <b>End point values</b>                      | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|--|--|--|---|---|
| Subject group type                           | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed                  | 93 <sup>[10]</sup>                                     | 95 <sup>[11]</sup>   | 90 <sup>[12]</sup>  | 86 <sup>[13]</sup>  |
| Units: Units on a scale                      |  |  |   |   |
| least squares mean (confidence interval 95%) | -1.08 (-1.35 to -0.82)                                 | -1.59 (-1.85 to -1.33)   | -2.09 (-2.37 to -1.82)  | -2.51 (-2.78 to -2.23)  |

Notes:

[10] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

[11] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

[12] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

[13] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

|  |   |  |  |  |
|--|---|--|--|--|
| <b>End point values</b>                      | Period 1<br>(Placebo-Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
| Subject group type                           | Reporting group   |  |  |  |
| Number of subjects analysed                  | 94 <sup>[14]</sup>  |  |  |  |
| Units: Units on a scale                      |   |  |  |  |
| least squares mean (confidence interval 95%) | -1.71 (-1.96 to -1.45)  |  |  |  |

Notes:

[14] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 188  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.007 <sup>[15]</sup>  |
| Method                                  | Mixed Model for Repeated Measures  |
| Parameter estimate                      | Least Squares (LS) Mean Difference   |
| Point estimate                          | -0.51  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | -0.87  |
| upper limit                             | -0.14  |

Notes:

[15] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 183   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[16]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Point estimate                          | -1.01   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -1.38   |
| upper limit                             | -0.64   |

Notes:

[16] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

| Statistical analysis title              | Statistical Analysis 3  |
|---|---|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Number of subjects included in analysis | 179   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[17]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Point estimate                          | -1.42   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -1.8  |
| upper limit                             | -1.05   |

Notes:

[17] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

| Statistical analysis title              | Statistical Analysis 4  |
|---|---|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 187   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[18]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Point estimate                          | -0.62   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -0.99   |
| upper limit                             | -0.26   |

Notes:

[18] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

## Secondary: Change in Clinical Disease Activity Index (CDAI) at Week 12

|                        |   |
|------------------------|---|
| End point title        | Change in Clinical Disease Activity Index (CDAI) at Week 12   |
| End point description: | CDAI is a composite index for assessing disease activity based on the sum of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS), and Physician's Global Assessment of Disease Activity (NRS). The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity. |
| End point type         | Secondary   |
| End point timeframe:   |   |
| Baseline to Week 12    |   |



| <b>End point values</b>                      | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|--|--|--|---|---|
| Subject group type                           | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed                  | 92 <sup>[19]</sup>                                     | 91 <sup>[20]</sup>   | 88 <sup>[21]</sup>  | 86 <sup>[22]</sup>  |
| Units: Units on a scale                      |  |  |   |   |
| least squares mean (confidence interval 95%) | -14.21 (-16.81 to -11.60)                              | -18.77 (-21.41 to -16.13)  | -22.21 (-24.94 to -19.48)   | -25.62 (-28.31 to -22.93)   |

Notes:

[19] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

[20] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

[21] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

[22] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

| <b>End point values</b>                      | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|--|---|--|--|--|
| Subject group type                           | Reporting group   |  |  |  |
| Number of subjects analysed                  | 93 <sup>[23]</sup>  |  |  |  |
| Units: Units on a scale                      |   |  |  |  |
| least squares mean (confidence interval 95%) | -19.50 (-22.06 to -16.94)   |  |  |  |

Notes:

[23] - ITT population subjects with non-missing baseline and at least one post-baseline value were included

## Statistical analyses

| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 183  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.014 <sup>[24]</sup>  |
| Method                                  | Mixed Model for Repeated Measures  |
| Parameter estimate                      | Least Squares (LS) Mean Difference   |
| Point estimate                          | -4.56  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | -8.21  |
| upper limit                             | -0.92  |

Notes:

[24] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

| Statistical analysis title              | Statistical Analysis 2  |
|---|---|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 180   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[25]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Point estimate                          | -8.01   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -11.7   |
| upper limit                             | -4.31   |

Notes:

[25] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

| Statistical analysis title              | Statistical Analysis 3  |
|---|---|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Number of subjects included in analysis | 178   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[26]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -15.1   |
| upper limit                             | -7.73   |

Notes:

[26] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

| Statistical analysis title              | Statistical Analysis 4  |
|---|---|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 185   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.004 <sup>[27]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Point estimate                          | -5.29   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | -8.89   |
| upper limit         | -1.69   |

Notes:

[27] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

## Secondary: Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12

|                 |   |
|-----------------|---|
| End point title | Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 |
|-----------------|---|

End point description:

Subjects who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria:

- ≥ 20% improvement in 68-tender joint count;
- ≥ 20% improvement in 66-swollen joint count; and
- ≥ 20% improvement in at least 3 of the 5 following parameters:
  - Physician's Global Assessment of Disease Activity (NRS)
  - Patient's Global Assessment of Disease Activity (NRS)
  - Patient's Assessment of Pain (NRS)
  - Health Assessment Questionnaire - Disability Index (HAQ-DI)
  - High-sensitivity C-reactive protein (hsCRP).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|----------------------------------|--|--|---|---|
| Subject group type               | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed      | 96 <sup>[28]</sup>                                     | 98 <sup>[29]</sup>   | 94 <sup>[30]</sup>  | 90 <sup>[31]</sup>  |
| Units: Percentage of subjects    |  |  |   |   |
| number (confidence interval 95%) | 28.1 (19.1 to 37.1)                                    | 52.7 (42.7 to 62.7)  | 59.3 (49.3 to 69.2)   | 74.4 (65.4 to 83.5)   |

Notes:

[28] - ITT analysis set participants were included (N=472)

[29] - ITT analysis set participants were included (N=472)

[30] - ITT analysis set participants were included (N=472)

[31] - ITT analysis set participants were included (N=472)

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|----------------------------------|---|--|--|--|
| Subject group type               | Reporting group   |  |  |  |
| Number of subjects analysed      | 94 <sup>[32]</sup>  |  |  |  |
| Units: Percentage of subjects    |   |  |  |  |
| number (confidence interval 95%) | 54.3 (44.2 to 64.3)   |  |  |  |

Notes:

[32] - ITT analysis set participants were included (N=472)

### Statistical analyses

| Statistical analysis title              | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 194  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001 <sup>[33]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference   |
| Point estimate                          | 24.7   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 12.1   |
| upper limit                             | 37.3   |

Notes:

[33] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

| Statistical analysis title              | Statistical Analysis 2  |
|---|---|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[34]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 30.2  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 17.4  |
| upper limit                             | 42.9  |

Notes:

[34] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

| Statistical analysis title | Statistical Analysis 3  |
|----------------------------|---|
| Comparison groups          | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 186                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001 <sup>[35]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference |
| Point estimate                          | 45.4                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 33.5                     |
| upper limit                             | 57.4                     |

Notes:

[35] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 4  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[36]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 24.6  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 11.9  |
| upper limit                             | 37.3  |

Notes:

[36] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

## Secondary: Percentage of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12

|                 |   |
|-----------------|---|
| End point title | Percentage of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12 |
|-----------------|---|

End point description:

Subjects who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:

- ≥ 70% improvement in 68-tender joint count;
- ≥ 70% improvement in 66-swollen joint count; and
- ≥ 70% improvement in at least 3 of the 5 following parameters:
  - Physician's Global Assessment of Disease Activity (NRS)
  - Patient's Global Assessment of Disease Activity (NRS)
  - Patient's Assessment of Pain (NRS)
  - Health Assessment Questionnaire - Disability Index (HAQ-DI)
  - High-sensitivity C-reactive protein (hsCRP).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| <b>End point values</b>          | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|----------------------------------|--|--|---|---|
| Subject group type               | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed      | 96 <sup>[37]</sup>                                     | 98 <sup>[38]</sup>   | 94 <sup>[39]</sup>  | 90 <sup>[40]</sup>  |
| Units: Percentage of subjects    |  |  |   |   |
| number (confidence interval 95%) | 3.1 (0.0 to 6.6)                                       | 9.2 (3.5 to 14.9)  | 12.8 (6.1 to 19.6)  | 13.3 (6.3 to 20.4)  |

Notes:

[37] - ITT analysis set subjects were included (N=472)

[38] - ITT analysis set subjects were included (N=472)

[39] - ITT analysis set subjects were included (N=472)

[40] - ITT analysis set subjects were included (N=472)

| <b>End point values</b>          | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|----------------------------------|---|--|--|--|
| Subject group type               | Reporting group   |  |  |  |
| Number of subjects analysed      | 94 <sup>[41]</sup>  |  |  |  |
| Units: Percentage of subjects    |   |  |  |  |
| number (confidence interval 95%) | 4.3 (0.2 to 8.3)  |  |  |  |

Notes:

[41] - ITT analysis set subjects were included (N=472)

## Statistical analyses

| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 194  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.031 <sup>[42]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference   |
| Point estimate                          | 6.5  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.6  |
| upper limit                             | 12.4   |

Notes:

[42] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.007 <sup>[43]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 9.8   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 2.7   |
| upper limit                             | 17  |

Notes:

[43] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 3  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Number of subjects included in analysis | 186   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.004 <sup>[44]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 10.9  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 3.6   |
| upper limit                             | 18.2  |

Notes:

[44] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 4  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.709 <sup>[45]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 0.9   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -4  |
| upper limit                             | 5.9   |

Notes:

[45] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

## Secondary: Percentage of Subjects Achieving Low Disease Activity (LDA) Defined by DAS28 (CRP) ≤ 3.2 at Week 12

|                 |   |
|-----------------|---|
| End point title | Percentage of Subjects Achieving Low Disease Activity (LDA) Defined by DAS28 (CRP) ≤ 3.2 at Week 12 |
|-----------------|---|

End point description:

Low disease activity (LDA) was defined as a DAS28 score less than or equal to 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS) and Physician's Global Assessment of Disease Activity (NRS), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|----------------------------------|--|--|---|---|
| Subject group type               | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed      | 96 <sup>[46]</sup>                                     | 98 <sup>[47]</sup>   | 94 <sup>[48]</sup>  | 90 <sup>[49]</sup>  |
| Units: Percentage of subjects    |  |  |   |   |
| number (confidence interval 95%) | 20.8 (12.7 to 29.0)                                    | 38.9 (29.2 to 48.6)  | 48.2 (38.0 to 58.3)   | 53.3 (43.0 to 63.6)   |

Notes:

[46] - ITT analysis set participants were included (N=472)

[47] - ITT analysis set participants were included (N=472)

[48] - ITT analysis set participants were included (N=472)

[49] - ITT analysis set participants were included (N=472)

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|----------------------------------|---|--|--|--|
| Subject group type               | Reporting group   |  |  |  |
| Number of subjects analysed      | 94 <sup>[50]</sup>  |  |  |  |
| Units: Percentage of subjects    |   |  |  |  |
| number (confidence interval 95%) | 45.7 (35.7 to 55.8)   |  |  |  |

Notes:

[50] - ITT analysis set participants were included (N=472)

## Statistical analyses

|                            |  |
|----------------------------|--|
| Statistical analysis title | Statistical Analysis 1   |
| Comparison groups          | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |



|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 194                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | = 0.006 <sup>[51]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference |
| Point estimate                          | 16.9                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 4.9                      |
| upper limit                             | 28.9                     |

Notes:

[51] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[52]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 25.8  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 13.5  |
| upper limit                             | 38.1  |

Notes:

[52] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 3  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Number of subjects included in analysis | 186   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[53]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 31.5  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 18.9  |
| upper limit                             | 44.2  |

Notes:

[53] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 4  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[54]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 23.2  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 11  |
| upper limit                             | 35.4  |

Notes:

[54] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

## Secondary: Percentage of Subjects Achieving LDA Defined by CDAI ≤ 10 at Week 12

|   |  |
|---|--|
| End point title   | Percentage of Subjects Achieving LDA Defined by CDAI ≤ 10 at Week 12 |
| End point description:  |  |
| Low disease activity based on CDAI is defined as a CDAI score less than or equal to 10. CDAI is a composite index for assessing disease activity based on the sum of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS), and Physician's Global Assessment of Disease Activity (NRS). The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Week 12   |  |

| End point values                 | Period 1 (Placebo-Controlled Period) Placebo | Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW | Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
|----------------------------------|--|---|--|--|
| Subject group type               | Reporting group                              | Reporting group   | Reporting group  | Reporting group  |
| Number of subjects analysed      | 96 <sup>[55]</sup>                           | 98 <sup>[56]</sup>                                      | 94 <sup>[57]</sup>                                       | 90 <sup>[58]</sup>                                       |
| Units: Percentage of subjects    |  |   |  |  |
| number (confidence interval 95%) | 21.9 (13.6 to 30.1)                          | 36.8 (27.3 to 46.4)                                     | 46.1 (36.0 to 56.2)                                      | 46.7 (36.4 to 57.0)                                      |

Notes:

[55] - ITT analysis set subjects were included (N=472)

[56] - ITT analysis set subjects were included (N=472)

[57] - ITT analysis set subjects were included (N=472)

[58] - ITT analysis set subjects were included (N=472)

|                  |                              |  |  |  |
|------------------|------------------------------|--|--|--|
| End point values | Period 1 (Placebo-Controlled |  |  |  |
|------------------|------------------------------|--|--|--|

|                                  |                             |  |  |  |
|----------------------------------|-----------------------------|--|--|--|
|                                  | Period) ABBV-154 340 mg E4W |  |  |  |
| Subject group type               | Reporting group             |  |  |  |
| Number of subjects analysed      | 94 <sup>[59]</sup>          |  |  |  |
| Units: Percentage of subjects    |                             |  |  |  |
| number (confidence interval 95%) | 36.2 (26.5 to 45.9)         |  |  |  |

Notes:

[59] - ITT analysis set subjects were included (N=472)

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 194  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.022 <sup>[60]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference   |
| Point estimate                          | 14.1   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 2  |
| upper limit                             | 26.2   |

Notes:

[60] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[61]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 22.8  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 10  |
| upper limit                             | 35.5  |

Notes:

[61] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | Statistical Analysis 3  |
| Comparison groups                 | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 186                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001 <sup>[62]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference |
| Point estimate                          | 24.3                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 11.6                     |
| upper limit                             | 37                       |

Notes:

[62] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 4   |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W v<br>Period 1 (Placebo-Controlled Period) Placebo |
| Number of subjects included in analysis | 190  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.042 <sup>[63]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference   |
| Point estimate                          | 12.6   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.5  |
| upper limit                             | 24.7   |

Notes:

[63] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

### **Secondary: Percentage of Subjects Achieving Clinical Remission (CR) Defined by DAS28 (CRP) < 2.6 at Week 12**

|  |   |
|--|---|
| End point title  | Percentage of Subjects Achieving Clinical Remission (CR)<br>Defined by DAS28 (CRP) < 2.6 at Week 12 |
| End point description:   |   |
| Clinical remission was defined as a DAS28 (CRP) score less than 2.6. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. |   |
| End point type   | Secondary   |
| End point timeframe:   |   |
| Week 12  |   |

| <b>End point values</b>          | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|----------------------------------|--|--|---|---|
| Subject group type               | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed      | 96 <sup>[64]</sup>                                     | 98 <sup>[65]</sup>   | 94 <sup>[66]</sup>  | 90 <sup>[67]</sup>  |
| Units: Percentage of subjects    |  |  |   |   |
| number (confidence interval 95%) | 12.5 (5.9 to 19.1)                                     | 18.4 (10.7 to 26.1)  | 33.0 (23.5 to 42.6)   | 37.8 (27.8 to 47.8)   |

Notes:

[64] - ITT analysis set subjects were included (N=472)

[65] - ITT analysis set subjects were included (N=472)

[66] - ITT analysis set subjects were included (N=472)

[67] - ITT analysis set subjects were included (N=472)

| <b>End point values</b>          | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|----------------------------------|---|--|--|--|
| Subject group type               | Reporting group   |  |  |  |
| Number of subjects analysed      | 94 <sup>[68]</sup>  |  |  |  |
| Units: Percentage of subjects    |   |  |  |  |
| number (confidence interval 95%) | 27.7 (18.6 to 36.7)   |  |  |  |

Notes:

[68] - ITT analysis set subjects were included (N=472)

## Statistical analyses

| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 194  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.296 <sup>[69]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference   |
| Point estimate                          | 5.1  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | -4.4   |
| upper limit                             | 14.6   |

Notes:

[69] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

| <b>Statistical analysis title</b> | Statistical Analysis 2  |
|-----------------------------------|---|
| Comparison groups                 | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 190                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001 <sup>[70]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference |
| Point estimate                          | 19.5                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 8.7                      |
| upper limit                             | 30.2                     |

Notes:

[70] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 3  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Number of subjects included in analysis | 186   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001 <sup>[71]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 25.5  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 14.3  |
| upper limit                             | 36.7  |

Notes:

[71] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 4  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.007 <sup>[72]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 14.1  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 3.8   |
| upper limit                             | 24.5  |

Notes:

[72] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

## Secondary: Percentage of Subjects Achieving CR Defined by CDAI ≤ 2.8 at Week 12

|                 |  |
|-----------------|--|
| End point title | Percentage of Subjects Achieving CR Defined by CDAI ≤ 2.8 at Week 12 |
|-----------------|--|

End point description:

Clinical Remission was defined by CDAI as a score less than or equal to 2.8. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS), and Physician's Global Assessment of Disease Activity (NRS). The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|----------------------------------|--|--|---|---|
| Subject group type               | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed      | 96   | 98   | 94  | 90  |
| Units: Percentage of subjects    |  |  |   |   |
| number (confidence interval 95%) | 2.1 (0.0 to 4.9)                                       | 9.2 (3.5 to 14.9)  | 4.3 (0.2 to 8.3)  | 4.4 (0.2 to 8.7)  |

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|----------------------------------|---|--|--|--|
| Subject group type               | Reporting group   |  |  |  |
| Number of subjects analysed      | 94  |  |  |  |
| Units: Percentage of subjects    |   |  |  |  |
| number (confidence interval 95%) | 3.2 (0.0 to 6.7)  |  |  |  |

## Statistical analyses

|   |  |
|---|--|
| Statistical analysis title              | Statistical Analysis 1   |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 194  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.017 <sup>[73]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference   |
| Point estimate                          | 7.1  |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 1.3     |
| upper limit         | 13      |

Notes:

[73] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 190   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.424 <sup>[74]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 2   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -2.8  |
| upper limit                             | 6.8   |

Notes:

[74] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 3  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
| Number of subjects included in analysis | 186   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.303 <sup>[75]</sup>   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Response Rate Difference  |
| Point estimate                          | 2.6   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -2.3  |
| upper limit                             | 7.5   |

Notes:

[75] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | Statistical Analysis 4  |
| Comparison groups                 | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |



|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 190                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | = 0.551 <sup>[76]</sup>  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Response Rate Difference |
| Point estimate                          | 1.3                      |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | -2.9                     |
| upper limit                             | 5.4                      |

Notes:

[76] - Cochran-Mantel-Haenszel (CMH) test adjusted for the stratification factors.

## Secondary: Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) to Week 12

|                 |  |
|-----------------|--|
| End point title | Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) to Week 12 |
|-----------------|--|

End point description:

The Health Assessment Questionnaire - Disability Index is a participant-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline to Week 12

| End point values                 | Period 1<br>(Placebo-<br>Controlled<br>Period) Placebo | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 40 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 150 mg<br>EOW | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>EOW |
|----------------------------------|--|--|---|---|
| Subject group type               | Reporting group  | Reporting group  | Reporting group   | Reporting group   |
| Number of subjects analysed      | 94   | 95   | 90  | 86  |
| Units: Percentage of subjects    |  |  |   |   |
| number (confidence interval 95%) | -0.08 (-0.19 to 0.03)                                  | -0.26 (-0.36 to -0.15)   | -0.33 (-0.45 to -0.22)  | -0.41 (-0.52 to -0.29)  |

| End point values            | Period 1<br>(Placebo-<br>Controlled<br>Period) ABBV-<br>154 340 mg<br>E4W |  |  |  |
|-----------------------------|---|--|--|--|
| Subject group type          | Reporting group   |  |  |  |
| Number of subjects analysed | 94  |  |  |  |

|                                  |                        |  |  |  |
|----------------------------------|------------------------|--|--|--|
| Units: Percentage of subjects    |                        |  |  |  |
| number (confidence interval 95%) | -0.29 (-0.39 to -0.18) |  |  |  |

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
| Number of subjects included in analysis | 189  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.022 <sup>[77]</sup>  |
| Method                                  | Mixed Model for Repeated Measures  |
| Parameter estimate                      | Least Squares (LS) Mean Difference   |
| Point estimate                          | -0.18  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | -0.33  |
| upper limit                             | -0.03  |

Notes:

[77] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
| Number of subjects included in analysis | 184   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.001 <sup>[78]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Point estimate                          | -0.25   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -0.41   |
| upper limit                             | -0.1  |

Notes:

[78] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | Statistical Analysis 3  |
| Comparison groups                 | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |

|   |                                    |
|---|------------------------------------|
| Number of subjects included in analysis | 180                                |
| Analysis specification                  | Pre-specified                      |
| Analysis type                           | superiority                        |
| P-value                                 | < 0.001 <sup>[79]</sup>            |
| Method                                  | Mixed Model for Repeated Measures  |
| Parameter estimate                      | Least Squares (LS) Mean Difference |
| Point estimate                          | -0.32                              |
| Confidence interval                     |                                    |
| level                                   | 95 %                               |
| sides                                   | 2-sided                            |
| lower limit                             | -0.48                              |
| upper limit                             | -0.17                              |

Notes:

[79] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 4  |
| Comparison groups                       | Period 1 (Placebo-Controlled Period) Placebo v Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
| Number of subjects included in analysis | 188   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.007 <sup>[80]</sup>   |
| Method                                  | Mixed Model for Repeated Measures   |
| Parameter estimate                      | Least Squares (LS) Mean Difference  |
| Point estimate                          | -0.21   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -0.36   |
| upper limit                             | -0.06   |

Notes:

[80] - MMRM model includes treatment, visit, treatment-by-visit interaction, stratification factors, and the baseline measurement as covariates.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All-cause mortality and adverse event tables include events reported from enrollment to end of study.

Adverse event reporting additional description:

Median time subjects were followed was 85 days for all groups in Period 1. For each LTE group, the median time subjects were followed was 412 days (Placebo-ABBV-154 150mg); 389 days (Placebo-ABBV-154 340mg); 390 days (ABBV-154 40mg EOW); 402.5 days (ABBV-154 150mg EOW), 404 days (ABBV-154 340mg EOW), and 380 days (ABBV-154 340mg E4W), respectively.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 26.0 |
|--------------------|------|

### Reporting groups

|                       |  |
|-----------------------|--|
| Reporting group title | Period 1 (Placebo-Controlled Period) Placebo |
|-----------------------|--|

Reporting group description:

Subjects in this group received placebo subcutaneously (SC) every other week (EOW) for 12 weeks in the placebo-controlled period and were re-randomized at 1:1 ratio to receive ABBV-154 150 mg or 340 mg SC EOW for 66 weeks in the long term extension (LTE) period.

|                       |   |
|-----------------------|---|
| Reporting group title | Period 1 (Placebo-Controlled Period) ABBV-154 40 mg EOW |
|-----------------------|---|

Reporting group description:

Subjects in this group received 40 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

One subject experienced an AE in Period 1 that was ongoing and resulted in death in Period 2.

|                       |  |
|-----------------------|--|
| Reporting group title | Period 1 (Placebo-Controlled Period) ABBV-154 150 mg EOW |
|-----------------------|--|

Reporting group description:

Subjects in this group received 150 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|                       |  |
|-----------------------|--|
| Reporting group title | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg EOW |
|-----------------------|--|

Reporting group description:

Subjects in this group received 340 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|                       |  |
|-----------------------|--|
| Reporting group title | Period 1 (Placebo-Controlled Period) ABBV-154 340 mg E4W |
|-----------------------|--|

Reporting group description:

Subjects in this group received 340 mg of ABBV-154 SC every 4 weeks (E4W) for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|                       |   |
|-----------------------|---|
| Reporting group title | Period 2 (Extension Period) Placebo to ABBV-154 150mg EOW |
|-----------------------|---|

Reporting group description:

Subjects in this group received placebo SC EOW for 12 weeks in the placebo-controlled period and then received ABBV-154 150mg SC EOW for 66 weeks in the LTE period.

|                       |  |
|-----------------------|--|
| Reporting group title | Period 2 (Extension Period) ABBV-154 40 mg EOW |
|-----------------------|--|

Reporting group description:

Subjects in this group received 40 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|                       |   |
|-----------------------|---|
| Reporting group title | Period 2 (Extension Period) Placebo to ABBV-154 340mg EOW |
|-----------------------|---|

Reporting group description:

Subjects in this group received placebo SC EOW for 12 weeks in the placebo-controlled period and then received ABBV-154 340mg SC EOW for 66 weeks in the LTE period.

|                       |   |
|-----------------------|---|
| Reporting group title | Period 2 (Extension Period) ABBV-154 340 mg EOW |
|-----------------------|---|

Reporting group description:

Subjects in this group received 340 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|                       |   |
|-----------------------|---|
| Reporting group title | Period 2 (Extension Period) ABBV-154 150 mg EOW |
|-----------------------|---|

Reporting group description:

Subjects in this group received 150 mg of ABBV-154 SC EOW for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

|                       |   |
|-----------------------|---|
| Reporting group title | Period 2 (Extension Period) ABBV-154 340 mg E4W |
|-----------------------|---|

Reporting group description:

Subjects in this group received 340 mg of ABBV-154 SC E4W for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.

| <b>Serious adverse events</b>  | Period 1 (Placebo-Controlled Period)<br>Placebo | Period 1 (Placebo-Controlled Period)<br>ABBV-154 40 mg<br>EOW | Period 1 (Placebo-Controlled Period)<br>ABBV-154 150 mg<br>EOW |
|--|---|---|--|
| Total subjects affected by serious adverse events  |   |   |  |
| subjects affected / exposed  | 2 / 96 (2.08%)                                  | 4 / 98 (4.08%)  | 6 / 95 (6.32%)   |
| number of deaths (all causes)  | 0   | 0   | 0  |
| number of deaths resulting from adverse events   | 0   | 0   | 0  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>ADENOCARCINOMA OF COLON |   |   |  |
| subjects affected / exposed  | 0 / 96 (0.00%)                                  | 0 / 98 (0.00%)  | 1 / 95 (1.05%)   |
| occurrences causally related to treatment / all  | 0 / 0   | 0 / 0   | 0 / 1  |
| deaths causally related to treatment / all   | 0 / 0   | 0 / 0   | 0 / 0  |
| BREAST CANCER  |   |   |  |
| subjects affected / exposed  | 0 / 96 (0.00%)                                  | 0 / 98 (0.00%)  | 0 / 95 (0.00%)   |
| occurrences causally related to treatment / all  | 0 / 0   | 0 / 0   | 0 / 0  |
| deaths causally related to treatment / all   | 0 / 0   | 0 / 0   | 0 / 0  |
| GLIOBLASTOMA   |   |   |  |
| subjects affected / exposed  | 0 / 96 (0.00%)                                  | 0 / 98 (0.00%)  | 0 / 95 (0.00%)   |
| occurrences causally related to treatment / all  | 0 / 0   | 0 / 0   | 0 / 0  |
| deaths causally related to treatment / all   | 0 / 0   | 0 / 0   | 0 / 0  |
| HEPATOCELLULAR CARCINOMA   |   |   |  |
| subjects affected / exposed  | 0 / 96 (0.00%)                                  | 0 / 98 (0.00%)  | 0 / 95 (0.00%)   |
| occurrences causally related to treatment / all  | 0 / 0   | 0 / 0   | 0 / 0  |
| deaths causally related to treatment / all   | 0 / 0   | 0 / 0   | 0 / 0  |
| Vascular disorders<br>AORTIC STENOSIS  |   |   |  |
| subjects affected / exposed  | 0 / 96 (0.00%)                                  | 0 / 98 (0.00%)  | 0 / 95 (0.00%)   |
| occurrences causally related to treatment / all  | 0 / 0   | 0 / 0   | 0 / 0  |
| deaths causally related to treatment / all   | 0 / 0   | 0 / 0   | 0 / 0  |

|  |                |                |                |
|--|----------------|----------------|----------------|
| General disorders and administration site conditions |                |                |                |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME                  |                |                |                |
| subjects affected / exposed                          | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 1 / 95 (1.05%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Immune system disorders                              |                |                |                |
| ANAPHYLACTIC REACTION                                |                |                |                |
| subjects affected / exposed                          | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders             |                |                |                |
| UTERINE POLYP  |                |                |                |
| subjects affected / exposed                          | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |                |                |                |
| ACUTE RESPIRATORY FAILURE                            |                |                |                |
| subjects affected / exposed                          | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMONITIS  |                |                |                |
| subjects affected / exposed                          | 1 / 96 (1.04%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all      | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Psychiatric disorders                                |                |                |                |
| CONFUSIONAL STATE                                    |                |                |                |
| subjects affected / exposed                          | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| DEPRESSION   |                |                |                |
| subjects affected / exposed                          | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural                     |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| complications                                   |                |                |                |
| ANKLE FRACTURE                                  |                |                |                |
| subjects affected / exposed                     | 1 / 96 (1.04%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PATELLA FRACTURE                                |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LIMB FRACTURE                                   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SKIN LACERATION                                 |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SPINAL COMPRESSION FRACTURE                     |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 1 / 98 (1.02%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVIAL RUPTURE                                |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 1 / 95 (1.05%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| TENDON INJURY                                   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| ACUTE CORONARY SYNDROME                         |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|                            |   |                |                |                |
|----------------------------|---|----------------|----------------|----------------|
| ATRIAL FIBRILLATION        | subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| BRADYCARDIA                | subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CARDIAC FAILURE CONGESTIVE | subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CORONARY ARTERY DISEASE    | subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| MYOCARDIAL INFARCTION      | subjects affected / exposed                     | 0 / 96 (0.00%) | 1 / 98 (1.02%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders   |   |                |                |                |
| CEREBRAL ISCHAEMIA         | subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| METABOLIC ENCEPHALOPATHY   | subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SEIZURE                    | subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
|                            | occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
|                            | deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| STROKE IN EVOLUTION        |   |                |                |                |



|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 1 / 95 (1.05%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SUBARACHNOID HAEMORRHAGE                        |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNCOPE   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| RETINAL DETACHMENT                              |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| ABDOMINAL PAIN UPPER                            |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COLITIS   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| FOOD POISONING                                  |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 1 / 95 (1.05%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| GASTRITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| HAEMATOCHESIA                                   |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| INCARCERATED INGUINAL HERNIA                    |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LARGE INTESTINE POLYP                           |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| CHOLANGITIS ACUTE                               |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 1 / 95 (1.05%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| EXOSTOSIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| RHEUMATOID ARTHRITIS                            |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVIAL CYST                                   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|   |                |                |                |
|---|----------------|----------------|----------------|
| TENOSYNOVITIS                                   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| BRONCHITIS                                      |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| BACTERAEMIA                                     |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19  |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 1 / 98 (1.02%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CELLULITIS                                      |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19 PNEUMONIA                              |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 1 / 98 (1.02%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1          | 0 / 0          |
| DIVERTICULITIS                                  |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| INFECTIOUS MONONUCLEOSIS                        |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| HERPES ZOSTER                                   |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LARYNGITIS                                      |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| NEUROLOGICAL INFECTION                          |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| OPPORTUNISTIC INFECTION                         |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| OSTEOMYELITIS                                   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMOCYSTIS JIROVECI<br>PNEUMONIA              |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMONIA                                       |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| POSTOPERATIVE WOUND INFECTION                   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PYELONEPHRITIS                                  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Q FEVER   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SEPSIS  |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 1 / 95 (1.05%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| STAPHYLOCOCCAL INFECTION                        |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 1 / 95 (1.05%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SINUSITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| URINARY TRACT INFECTION                         |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| WOUND INFECTION                                 |                |                |                |
| STAPHYLOCOCCAL                                  |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 0 / 98 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| HYPOGLYCAEMIA                                   |                |                |                |
| subjects affected / exposed                     | 0 / 96 (0.00%) | 1 / 98 (1.02%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>  | Period 1 (Placebo-Controlled Period)<br>ABBV-154 340 mg<br>EOW | Period 1 (Placebo-Controlled Period)<br>ABBV-154 340 mg<br>E4W | Period 2 (Extension Period) Placebo to<br>ABBV-154 150mg<br>EOW |
|--|--|--|---|
| Total subjects affected by serious adverse events  |  |  |   |
| subjects affected / exposed  | 5 / 90 (5.56%)   | 3 / 94 (3.19%)   | 3 / 45 (6.67%)  |
| number of deaths (all causes)  | 0  | 0  | 0   |
| number of deaths resulting from adverse events   | 0  | 0  | 0   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>ADENOCARCINOMA OF COLON |  |  |   |
| subjects affected / exposed  | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences causally related to treatment / all  | 0 / 0  | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all   | 0 / 0  | 0 / 0  | 0 / 0   |
| BREAST CANCER  |  |  |   |
| subjects affected / exposed  | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences causally related to treatment / all  | 0 / 0  | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all   | 0 / 0  | 0 / 0  | 0 / 0   |
| GLIOBLASTOMA   |  |  |   |
| subjects affected / exposed  | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences causally related to treatment / all  | 0 / 0  | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all   | 0 / 0  | 0 / 0  | 0 / 0   |
| HEPATOCELLULAR CARCINOMA   |  |  |   |
| subjects affected / exposed  | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences causally related to treatment / all  | 0 / 0  | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all   | 0 / 0  | 0 / 0  | 0 / 0   |
| Vascular disorders<br>AORTIC STENOSIS  |  |  |   |
| subjects affected / exposed  | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences causally related to treatment / all  | 0 / 0  | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all   | 0 / 0  | 0 / 0  | 0 / 0   |
| General disorders and administration site conditions<br>MULTIPLE ORGAN DYSFUNCTION SYNDROME    |  |  |   |
| subjects affected / exposed  | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences causally related to treatment / all  | 0 / 0  | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all   | 0 / 0  | 0 / 0  | 0 / 0   |
| Immune system disorders  |  |  |   |

|   |                |                |                |
|---|----------------|----------------|----------------|
| ANAPHYLACTIC REACTION                           |                |                |                |
| subjects affected / exposed                     | 1 / 90 (1.11%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                |                |                |
| UTERINE POLYP                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| ACUTE RESPIRATORY FAILURE                       |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMONITIS                                     |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Psychiatric disorders                           |                |                |                |
| CONFUSIONAL STATE                               |                |                |                |
| subjects affected / exposed                     | 1 / 90 (1.11%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| DEPRESSION                                      |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications  |                |                |                |
| ANKLE FRACTURE                                  |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PATELLA FRACTURE                                |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LIMB FRACTURE                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SKIN LACERATION                                 |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SPINAL COMPRESSION FRACTURE                     |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVIAL RUPTURE                                |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| TENDON INJURY                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| ACUTE CORONARY SYNDROME                         |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| ATRIAL FIBRILLATION                             |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| BRADYCARDIA                                     |                |                |                |



|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CARDIAC FAILURE CONGESTIVE                      |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CORONARY ARTERY DISEASE                         |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| MYOCARDIAL INFARCTION                           |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| CEREBRAL ISCHAEMIA                              |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| METABOLIC ENCEPHALOPATHY                        |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SEIZURE   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| STROKE IN EVOLUTION                             |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SUBARACHNOID HAEMORRHAGE                        |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 1 / 45 (2.22%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNCOPE   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 1 / 94 (1.06%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| RETINAL DETACHMENT                              |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| ABDOMINAL PAIN UPPER                            |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COLITIS   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| FOOD POISONING                                  |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| GASTRITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 1 / 45 (2.22%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| HAEMATOCHEZIA                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| INCARCERATED INGUINAL HERNIA                    |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LARGE INTESTINE POLYP                           |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| CHOLANGITIS ACUTE                               |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| EXOSTOSIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| RHEUMATOID ARTHRITIS                            |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVIAL CYST                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| TENOSYNOVITIS                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|   |                                  |                                  |                                  |
|---|----------------------------------|----------------------------------|----------------------------------|
| Infections and infestations<br>BRONCHITIS<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all | 0 / 90 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 94 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| BACTERAEemia<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                              | 0 / 90 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 94 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| COVID-19<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                  | 0 / 90 (0.00%)<br>0 / 0<br>0 / 0 | 1 / 94 (1.06%)<br>1 / 1<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| CELLULITIS<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                                | 0 / 90 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 94 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| COVID-19 PNEUMONIA<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                        | 1 / 90 (1.11%)<br>0 / 1<br>0 / 0 | 0 / 94 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| DIVERTICULITIS<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                            | 0 / 90 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 94 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| INFECTIOUS MONONUCLEOSIS<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                  | 0 / 90 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 94 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| HERPES ZOSTER<br>subjects affected / exposed<br>occurrences causally related to treatment / all<br>deaths causally related to treatment / all                             | 0 / 90 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 94 (0.00%)<br>0 / 0<br>0 / 0 | 0 / 45 (0.00%)<br>0 / 0<br>0 / 0 |
| LARYNGITIS  |                                  |                                  |                                  |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| NEUROLOGICAL INFECTION                          |                |                |                |
| subjects affected / exposed                     | 1 / 90 (1.11%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| OPPORTUNISTIC INFECTION                         |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| OSTEOMYELITIS                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMOCYSTIS JIROVECII PNEUMONIA                |                |                |                |
| subjects affected / exposed                     | 1 / 90 (1.11%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMONIA                                       |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 1 / 94 (1.06%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| POSTOPERATIVE WOUND INFECTION                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PYELONEPHRITIS                                  |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 1 / 45 (2.22%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Q FEVER   |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 1 / 45 (2.22%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SEPSIS  |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| STAPHYLOCOCCAL INFECTION                        |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SINUSITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| URINARY TRACT INFECTION                         |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| WOUND INFECTION                                 |                |                |                |
| STAPHYLOCOCCAL                                  |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| HYPOGLYCAEMIA                                   |                |                |                |
| subjects affected / exposed                     | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events                            | Period 2 (Extension Period) ABBV-154 40 mg EOW | Period 2 (Extension Period) Placebo to ABBV-154 340mg EOW | Period 2 (Extension Period) ABBV-154 340 mg EOW |
|---|--|---|---|
| Total subjects affected by serious adverse events |  |   |   |
| subjects affected / exposed                       | 7 / 91 (7.69%)                                 | 6 / 46 (13.04%)   | 10 / 84 (11.90%)                                |
| number of deaths (all causes)                     | 1  | 0   | 0   |

|  |                |                |                |
|--|----------------|----------------|----------------|
| number of deaths resulting from adverse events   | 0              | 0              | 0              |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>ADENOCARCINOMA OF COLON |                |                |                |
| subjects affected / exposed  | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all  | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0          |
| BREAST CANCER  |                |                |                |
| subjects affected / exposed  | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all  | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0          |
| GLIOBLASTOMA   |                |                |                |
| subjects affected / exposed  | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all  | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0          |
| HEPATOCELLULAR CARCINOMA   |                |                |                |
| subjects affected / exposed  | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all  | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0          |
| Vascular disorders   |                |                |                |
| AORTIC STENOSIS  |                |                |                |
| subjects affected / exposed  | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all  | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0          |
| General disorders and administration site conditions   |                |                |                |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME  |                |                |                |
| subjects affected / exposed  | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all  | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0          |
| Immune system disorders  |                |                |                |
| ANAPHYLACTIC REACTION  |                |                |                |
| subjects affected / exposed  | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all  | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all   | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast   |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| disorders                                       |                |                |                |
| UTERINE POLYP                                   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| ACUTE RESPIRATORY FAILURE                       |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMONITIS                                     |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Psychiatric disorders                           |                |                |                |
| CONFUSIONAL STATE                               |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| DEPRESSION                                      |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications  |                |                |                |
| ANKLE FRACTURE                                  |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PATELLA FRACTURE                                |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LIMB FRACTURE                                   |                |                |                |



|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SKIN LACERATION                                 |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SPINAL COMPRESSION FRACTURE                     |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVIAL RUPTURE                                |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| TENDON INJURY                                   |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| ACUTE CORONARY SYNDROME                         |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| ATRIAL FIBRILLATION                             |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| BRADYCARDIA                                     |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CARDIAC FAILURE CONGESTIVE                      |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CORONARY ARTERY DISEASE                         |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| MYOCARDIAL INFARCTION                           |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| CEREBRAL ISCHAEMIA                              |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| METABOLIC ENCEPHALOPATHY                        |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SEIZURE   |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| STROKE IN EVOLUTION                             |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SUBARACHNOID HAEMORRHAGE                        |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNCOPE   |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| RETINAL DETACHMENT                              |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| ABDOMINAL PAIN UPPER                            |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COLITIS   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| FOOD POISONING                                  |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| GASTRITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| HAEMATOCHYZIA                                   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| INCARCERATED INGUINAL HERNIA                    |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LARGE INTESTINE POLYP                           |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 91 (0.00%) | 1 / 46 (2.17%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| CHOLANGITIS ACUTE                               |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| EXOSTOSIS                                       |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| RHEUMATOID ARTHRITIS                            |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 1 / 46 (2.17%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVIAL CYST                                   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SYNOVITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| TENOSYNOVITIS                                   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| BRONCHITIS                                      |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 1 / 46 (2.17%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|   |                |                |                |
|---|----------------|----------------|----------------|
| BACTERAEemia                                    |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19  |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| CELLULITIS                                      |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19 PNEUMONIA                              |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| DIVERTICULITIS                                  |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 1 / 46 (2.17%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| INFECTIOUS MONONUCLEOSIS                        |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| HERPES ZOSTER                                   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| LARYNGITIS                                      |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 1 / 46 (2.17%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| NEUROLOGICAL INFECTION                          |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| OPPORTUNISTIC INFECTION                         |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| OSTEOMYELITIS                                   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMOCYSTIS JIROVECI<br>PNEUMONIA              |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PNEUMONIA                                       |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 1 / 46 (2.17%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| POSTOPERATIVE WOUND INFECTION                   |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| PYELONEPHRITIS                                  |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Q FEVER   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SEPSIS  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| STAPHYLOCOCCAL INFECTION                        |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| SINUSITIS                                       |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| URINARY TRACT INFECTION                         |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| WOUND INFECTION                                 |                |                |                |
| STAPHYLOCOCCAL                                  |                |                |                |
| subjects affected / exposed                     | 1 / 91 (1.10%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| HYPOGLYCAEMIA                                   |                |                |                |
| subjects affected / exposed                     | 0 / 91 (0.00%) | 0 / 46 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events  | Period 2 (Extension Period) ABBV-154 150 mg EOW | Period 2 (Extension Period) ABBV-154 340 mg E4W |  |
|---|---|---|--|
| Total subjects affected by serious adverse events                   |   |   |  |
| subjects affected / exposed   | 8 / 86 (9.30%)                                  | 9 / 89 (10.11%)                                 |  |
| number of deaths (all causes)                                       | 0   | 3   |  |
| number of deaths resulting from adverse events                      | 0   | 3   |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |   |  |
| ADENOCARCINOMA OF COLON   |   |   |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                                 | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all             | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all                  | 0 / 0          | 0 / 0          |  |
| <b>BREAST CANCER</b>  |                |                |  |
| subjects affected / exposed                                 | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all             | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all                  | 0 / 0          | 0 / 0          |  |
| <b>GLIOBLASTOMA</b>   |                |                |  |
| subjects affected / exposed                                 | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all             | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all                  | 0 / 0          | 0 / 0          |  |
| <b>HEPATOCELLULAR CARCINOMA</b>                             |                |                |  |
| subjects affected / exposed                                 | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all             | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all                  | 0 / 0          | 0 / 0          |  |
| <b>Vascular disorders</b>                                   |                |                |  |
| <b>AORTIC STENOSIS</b>                                      |                |                |  |
| subjects affected / exposed                                 | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all             | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all                  | 0 / 0          | 0 / 0          |  |
| <b>General disorders and administration site conditions</b> |                |                |  |
| <b>MULTIPLE ORGAN DYSFUNCTION SYNDROME</b>                  |                |                |  |
| subjects affected / exposed                                 | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all             | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all                  | 0 / 0          | 0 / 0          |  |
| <b>Immune system disorders</b>                              |                |                |  |
| <b>ANAPHYLACTIC REACTION</b>                                |                |                |  |
| subjects affected / exposed                                 | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all             | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all                  | 0 / 0          | 0 / 0          |  |
| <b>Reproductive system and breast disorders</b>             |                |                |  |
| <b>UTERINE POLYP</b>  |                |                |  |



|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Respiratory, thoracic and mediastinal disorders |                |                |  |
| ACUTE RESPIRATORY FAILURE                       |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1          |  |
| PNEUMONITIS                                     |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Psychiatric disorders                           |                |                |  |
| CONFUSIONAL STATE                               |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| DEPRESSION                                      |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Injury, poisoning and procedural complications  |                |                |  |
| ANKLE FRACTURE                                  |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| PATELLA FRACTURE                                |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| LIMB FRACTURE                                   |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SKIN LACERATION                                 |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SPINAL COMPRESSION FRACTURE                     |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SYNOVIAL RUPTURE                                |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| TENDON INJURY                                   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Cardiac disorders                               |                |                |  |
| ACUTE CORONARY SYNDROME                         |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| ATRIAL FIBRILLATION                             |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| BRADYCARDIA                                     |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| CARDIAC FAILURE CONGESTIVE                      |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1          |  |
| CORONARY ARTERY DISEASE                         |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| MYOCARDIAL INFARCTION                           |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Nervous system disorders                        |                |                |  |
| CEREBRAL ISCHAEMIA                              |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1          |  |
| METABOLIC ENCEPHALOPATHY                        |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SEIZURE   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| STROKE IN EVOLUTION                             |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SUBARACHNOID HAEMORRHAGE                        |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SYNCOPE   |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 1 / 86 (1.16%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Eye disorders                                   |                |                |  |
| RETINAL DETACHMENT                              |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Gastrointestinal disorders                      |                |                |  |
| ABDOMINAL PAIN UPPER                            |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| COLITIS   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| FOOD POISONING                                  |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| GASTRITIS                                       |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| HAEMATOCHESIA                                   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| INCARCERATED INGUINAL HERNIA                    |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| LARGE INTESTINE POLYP                           |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Hepatobiliary disorders                         |                |                |  |
| CHOLANGITIS ACUTE                               |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Musculoskeletal and connective tissue disorders |                |                |  |
| EXOSTOSIS                                       |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| RHEUMATOID ARTHRITIS                            |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SYNOVIAL CYST                                   |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SYNOVITIS                                       |                |                |  |
| subjects affected / exposed                     | 2 / 86 (2.33%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 3          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| TENOSYNOVITIS                                   |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Infections and infestations                     |                |                |  |
| BRONCHITIS                                      |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |

|   |                |                |  |
|---|----------------|----------------|--|
| BACTERAEemia                                    |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| COVID-19  |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| CELLULITIS                                      |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| COVID-19 PNEUMONIA                              |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| DIVERTICULITIS                                  |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| INFECTIOUS MONONUCLEOSIS                        |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| HERPES ZOSTER                                   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| LARYNGITIS                                      |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| NEUROLOGICAL INFECTION                          |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| OPPORTUNISTIC INFECTION                         |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| OSTEOMYELITIS                                   |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| PNEUMOCYSTIS JIROVECI<br>PNEUMONIA              |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| PNEUMONIA                                       |                |                |  |
| subjects affected / exposed                     | 1 / 86 (1.16%) | 2 / 89 (2.25%) |  |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 3          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| POSTOPERATIVE WOUND INFECTION                   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| PYELONEPHRITIS                                  |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 1 / 89 (1.12%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Q FEVER   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SEPSIS  |                |                |  |

|   |                |                |  |
|---|----------------|----------------|--|
| subjects affected / exposed                     | 0 / 86 (0.00%) | 2 / 89 (2.25%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 2          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| STAPHYLOCOCCAL INFECTION                        |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| SINUSITIS                                       |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| URINARY TRACT INFECTION                         |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| WOUND INFECTION                                 |                |                |  |
| STAPHYLOCOCCAL                                  |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |
| Metabolism and nutrition disorders              |                |                |  |
| HYPOGLYCAEMIA                                   |                |                |  |
| subjects affected / exposed                     | 0 / 86 (0.00%) | 0 / 89 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          |  |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events                            | Period 1 (Placebo-Controlled Period)<br>Placebo | Period 1 (Placebo-Controlled Period)<br>ABBV-154 40 mg<br>EOW | Period 1 (Placebo-Controlled Period)<br>ABBV-154 150 mg<br>EOW |
|---|---|---|--|
| Total subjects affected by non-serious adverse events |   |   |  |
| subjects affected / exposed                           | 25 / 96 (26.04%)                                | 43 / 98 (43.88%)  | 26 / 95 (27.37%)   |
| Injury, poisoning and procedural complications        |   |   |  |



|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| CONTUSION<br>subjects affected / exposed<br>occurrences (all)  | 0 / 96 (0.00%)<br>0 | 0 / 98 (0.00%)<br>0 | 3 / 95 (3.16%)<br>3 |
| FALL<br>subjects affected / exposed<br>occurrences (all)   | 1 / 96 (1.04%)<br>1 | 1 / 98 (1.02%)<br>1 | 0 / 95 (0.00%)<br>0 |
| Vascular disorders<br>HYPERTENSION<br>subjects affected / exposed<br>occurrences (all)   | 0 / 96 (0.00%)<br>0 | 0 / 98 (0.00%)<br>0 | 2 / 95 (2.11%)<br>2 |
| Nervous system disorders<br>HEADACHE<br>subjects affected / exposed<br>occurrences (all)   | 3 / 96 (3.13%)<br>3 | 4 / 98 (4.08%)<br>4 | 3 / 95 (3.16%)<br>3 |
| General disorders and administration<br>site conditions<br>INJECTION SITE DISCOLOURATION<br>subjects affected / exposed<br>occurrences (all) | 0 / 96 (0.00%)<br>0 | 3 / 98 (3.06%)<br>4 | 1 / 95 (1.05%)<br>2 |
| INJECTION SITE BRUISING<br>subjects affected / exposed<br>occurrences (all)  | 2 / 96 (2.08%)<br>2 | 3 / 98 (3.06%)<br>4 | 0 / 95 (0.00%)<br>0 |
| INJECTION SITE ERYTHEMA<br>subjects affected / exposed<br>occurrences (all)  | 1 / 96 (1.04%)<br>3 | 3 / 98 (3.06%)<br>7 | 1 / 95 (1.05%)<br>1 |
| OEDEMA PERIPHERAL<br>subjects affected / exposed<br>occurrences (all)  | 0 / 96 (0.00%)<br>0 | 0 / 98 (0.00%)<br>0 | 0 / 95 (0.00%)<br>0 |
| PYREXIA<br>subjects affected / exposed<br>occurrences (all)  | 0 / 96 (0.00%)<br>0 | 0 / 98 (0.00%)<br>0 | 1 / 95 (1.05%)<br>1 |
| Gastrointestinal disorders<br>NAUSEA<br>subjects affected / exposed<br>occurrences (all)   | 1 / 96 (1.04%)<br>1 | 0 / 98 (0.00%)<br>0 | 0 / 95 (0.00%)<br>0 |
| DIARRHOEA  |                     |                     |                     |

|   |  |   |  |
|---|--|---|--|
| subjects affected / exposed<br>occurrences (all)  | 1 / 96 (1.04%)<br>1  | 2 / 98 (2.04%)<br>2   | 3 / 95 (3.16%)<br>5  |
| Skin and subcutaneous tissue disorders<br>RASH<br>subjects affected / exposed<br>occurrences (all)  | 0 / 96 (0.00%)<br>0  | 2 / 98 (2.04%)<br>2   | 3 / 95 (3.16%)<br>5  |
| Musculoskeletal and connective tissue disorders<br>ARTHRALGIA<br>subjects affected / exposed<br>occurrences (all)<br><br>BACK PAIN<br>subjects affected / exposed<br>occurrences (all)<br><br>RHEUMATOID ARTHRITIS<br>subjects affected / exposed<br>occurrences (all)  | 0 / 96 (0.00%)<br>0<br><br>2 / 96 (2.08%)<br>2<br><br>7 / 96 (7.29%)<br>8  | 2 / 98 (2.04%)<br>2<br><br>3 / 98 (3.06%)<br>4<br><br>5 / 98 (5.10%)<br>6   | 1 / 95 (1.05%)<br>1<br><br>0 / 95 (0.00%)<br>0<br><br>2 / 95 (2.11%)<br>2  |
| Infections and infestations<br>BRONCHITIS<br>subjects affected / exposed<br>occurrences (all)<br><br>COVID-19<br>subjects affected / exposed<br>occurrences (all)<br><br>INFLUENZA<br>subjects affected / exposed<br>occurrences (all)<br><br>NASOPHARYNGITIS<br>subjects affected / exposed<br>occurrences (all)<br><br>PHARYNGITIS<br>subjects affected / exposed<br>occurrences (all)<br><br>UPPER RESPIRATORY TRACT<br>INFECTION<br>subjects affected / exposed<br>occurrences (all)<br><br>URINARY TRACT INFECTION | 2 / 96 (2.08%)<br>2<br><br>1 / 96 (1.04%)<br>1<br><br>0 / 96 (0.00%)<br>0<br><br>2 / 96 (2.08%)<br>2<br><br>0 / 96 (0.00%)<br>0<br><br>1 / 96 (1.04%)<br>1 | 2 / 98 (2.04%)<br>2<br><br>13 / 98 (13.27%)<br>13<br><br>1 / 98 (1.02%)<br>1<br><br>2 / 98 (2.04%)<br>2<br><br>0 / 98 (0.00%)<br>0<br><br>3 / 98 (3.06%)<br>3 | 1 / 95 (1.05%)<br>1<br><br>5 / 95 (5.26%)<br>5<br><br>0 / 95 (0.00%)<br>0<br><br>4 / 95 (4.21%)<br>5<br><br>0 / 95 (0.00%)<br>0<br><br>0 / 95 (0.00%)<br>0 |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 3 / 96 (3.13%) | 5 / 98 (5.10%) | 1 / 95 (1.05%) |
| occurrences (all)           | 3              | 5              | 1              |

| <b>Non-serious adverse events</b>                     | Period 1 (Placebo-Controlled Period)<br>ABBV-154 340 mg<br>EOW | Period 1 (Placebo-Controlled Period)<br>ABBV-154 340 mg<br>E4W | Period 2 (Extension Period) Placebo to<br>ABBV-154 150mg<br>EOW |
|---|--|--|---|
| Total subjects affected by non-serious adverse events |  |  |   |
| subjects affected / exposed                           | 26 / 90 (28.89%)   | 27 / 94 (28.72%)   | 31 / 45 (68.89%)  |
| Injury, poisoning and procedural complications        |  |  |   |
| CONTUSION   |  |  |   |
| subjects affected / exposed                           | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences (all)                                     | 0  | 0  | 0   |
| FALL  |  |  |   |
| subjects affected / exposed                           | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences (all)                                     | 0  | 0  | 0   |
| Vascular disorders                                    |  |  |   |
| HYPERTENSION  |  |  |   |
| subjects affected / exposed                           | 2 / 90 (2.22%)   | 1 / 94 (1.06%)   | 1 / 45 (2.22%)  |
| occurrences (all)                                     | 2  | 1  | 1   |
| Nervous system disorders                              |  |  |   |
| HEADACHE  |  |  |   |
| subjects affected / exposed                           | 4 / 90 (4.44%)   | 2 / 94 (2.13%)   | 2 / 45 (4.44%)  |
| occurrences (all)                                     | 4  | 2  | 2   |
| General disorders and administration site conditions  |  |  |   |
| INJECTION SITE DISCOLOURATION                         |  |  |   |
| subjects affected / exposed                           | 4 / 90 (4.44%)   | 1 / 94 (1.06%)   | 4 / 45 (8.89%)  |
| occurrences (all)                                     | 4  | 1  | 5   |
| INJECTION SITE BRUISING                               |  |  |   |
| subjects affected / exposed                           | 1 / 90 (1.11%)   | 1 / 94 (1.06%)   | 0 / 45 (0.00%)  |
| occurrences (all)                                     | 1  | 1  | 0   |
| INJECTION SITE ERYTHEMA                               |  |  |   |
| subjects affected / exposed                           | 3 / 90 (3.33%)   | 6 / 94 (6.38%)   | 2 / 45 (4.44%)  |
| occurrences (all)                                     | 6  | 7  | 3   |
| OEDEMA PERIPHERAL                                     |  |  |   |
| subjects affected / exposed                           | 0 / 90 (0.00%)   | 0 / 94 (0.00%)   | 0 / 45 (0.00%)  |
| occurrences (all)                                     | 0  | 0  | 0   |
| PYREXIA   |  |  |   |

|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 2 / 90 (2.22%)<br>2 | 0 / 94 (0.00%)<br>0 | 2 / 45 (4.44%)<br>2 |
| Gastrointestinal disorders                       |                     |                     |                     |
| NAUSEA   |                     |                     |                     |
| subjects affected / exposed                      | 1 / 90 (1.11%)      | 3 / 94 (3.19%)      | 0 / 45 (0.00%)      |
| occurrences (all)                                | 1                   | 3                   | 0                   |
| DIARRHOEA  |                     |                     |                     |
| subjects affected / exposed                      | 2 / 90 (2.22%)      | 0 / 94 (0.00%)      | 2 / 45 (4.44%)      |
| occurrences (all)                                | 2                   | 0                   | 2                   |
| Skin and subcutaneous tissue disorders           |                     |                     |                     |
| RASH   |                     |                     |                     |
| subjects affected / exposed                      | 2 / 90 (2.22%)      | 2 / 94 (2.13%)      | 0 / 45 (0.00%)      |
| occurrences (all)                                | 2                   | 2                   | 0                   |
| Musculoskeletal and connective tissue disorders  |                     |                     |                     |
| ARTHRALGIA                                       |                     |                     |                     |
| subjects affected / exposed                      | 1 / 90 (1.11%)      | 0 / 94 (0.00%)      | 1 / 45 (2.22%)      |
| occurrences (all)                                | 1                   | 0                   | 1                   |
| BACK PAIN  |                     |                     |                     |
| subjects affected / exposed                      | 2 / 90 (2.22%)      | 1 / 94 (1.06%)      | 1 / 45 (2.22%)      |
| occurrences (all)                                | 2                   | 1                   | 1                   |
| RHEUMATOID ARTHRITIS                             |                     |                     |                     |
| subjects affected / exposed                      | 1 / 90 (1.11%)      | 2 / 94 (2.13%)      | 5 / 45 (11.11%)     |
| occurrences (all)                                | 1                   | 2                   | 6                   |
| Infections and infestations                      |                     |                     |                     |
| BRONCHITIS                                       |                     |                     |                     |
| subjects affected / exposed                      | 1 / 90 (1.11%)      | 0 / 94 (0.00%)      | 2 / 45 (4.44%)      |
| occurrences (all)                                | 1                   | 0                   | 2                   |
| COVID-19   |                     |                     |                     |
| subjects affected / exposed                      | 2 / 90 (2.22%)      | 7 / 94 (7.45%)      | 12 / 45 (26.67%)    |
| occurrences (all)                                | 2                   | 7                   | 12                  |
| INFLUENZA  |                     |                     |                     |
| subjects affected / exposed                      | 0 / 90 (0.00%)      | 0 / 94 (0.00%)      | 5 / 45 (11.11%)     |
| occurrences (all)                                | 0                   | 0                   | 6                   |
| NASOPHARYNGITIS                                  |                     |                     |                     |
| subjects affected / exposed                      | 1 / 90 (1.11%)      | 3 / 94 (3.19%)      | 4 / 45 (8.89%)      |
| occurrences (all)                                | 1                   | 3                   | 4                   |

|                                   |                |                |                 |
|-----------------------------------|----------------|----------------|-----------------|
| PHARYNGITIS                       |                |                |                 |
| subjects affected / exposed       | 0 / 90 (0.00%) | 0 / 94 (0.00%) | 0 / 45 (0.00%)  |
| occurrences (all)                 | 0              | 0              | 0               |
| UPPER RESPIRATORY TRACT INFECTION |                |                |                 |
| subjects affected / exposed       | 4 / 90 (4.44%) | 4 / 94 (4.26%) | 9 / 45 (20.00%) |
| occurrences (all)                 | 5              | 4              | 11              |
| URINARY TRACT INFECTION           |                |                |                 |
| subjects affected / exposed       | 2 / 90 (2.22%) | 0 / 94 (0.00%) | 8 / 45 (17.78%) |
| occurrences (all)                 | 2              | 0              | 10              |

| <b>Non-serious adverse events</b>                     | Period 2 (Extension Period) ABBV-154 40 mg EOW | Period 2 (Extension Period) Placebo to ABBV-154 340mg EOW | Period 2 (Extension Period) ABBV-154 340 mg EOW |
|---|--|---|---|
| Total subjects affected by non-serious adverse events |  |   |   |
| subjects affected / exposed                           | 54 / 91 (59.34%)                               | 25 / 46 (54.35%)  | 52 / 84 (61.90%)                                |
| Injury, poisoning and procedural complications        |  |   |   |
| CONTUSION   |  |   |   |
| subjects affected / exposed                           | 2 / 91 (2.20%)                                 | 1 / 46 (2.17%)  | 3 / 84 (3.57%)                                  |
| occurrences (all)                                     | 2  | 1   | 3   |
| FALL  |  |   |   |
| subjects affected / exposed                           | 6 / 91 (6.59%)                                 | 0 / 46 (0.00%)  | 0 / 84 (0.00%)                                  |
| occurrences (all)                                     | 6  | 0   | 0   |
| Vascular disorders                                    |  |   |   |
| HYPERTENSION  |  |   |   |
| subjects affected / exposed                           | 4 / 91 (4.40%)                                 | 1 / 46 (2.17%)  | 4 / 84 (4.76%)                                  |
| occurrences (all)                                     | 4  | 1   | 4   |
| Nervous system disorders                              |  |   |   |
| HEADACHE  |  |   |   |
| subjects affected / exposed                           | 3 / 91 (3.30%)                                 | 1 / 46 (2.17%)  | 3 / 84 (3.57%)                                  |
| occurrences (all)                                     | 3  | 1   | 5   |
| General disorders and administration site conditions  |  |   |   |
| INJECTION SITE DISCOLOURATION                         |  |   |   |
| subjects affected / exposed                           | 2 / 91 (2.20%)                                 | 3 / 46 (6.52%)  | 3 / 84 (3.57%)                                  |
| occurrences (all)                                     | 2  | 5   | 3   |
| INJECTION SITE BRUISING                               |  |   |   |
| subjects affected / exposed                           | 2 / 91 (2.20%)                                 | 5 / 46 (10.87%)   | 2 / 84 (2.38%)                                  |
| occurrences (all)                                     | 3  | 13  | 2   |

|   |                        |                     |                     |
|---|------------------------|---------------------|---------------------|
| INJECTION SITE ERYTHEMA<br>subjects affected / exposed<br>occurrences (all) | 7 / 91 (7.69%)<br>35   | 3 / 46 (6.52%)<br>9 | 5 / 84 (5.95%)<br>8 |
| OEDEMA PERIPHERAL<br>subjects affected / exposed<br>occurrences (all)       | 0 / 91 (0.00%)<br>0    | 0 / 46 (0.00%)<br>0 | 7 / 84 (8.33%)<br>7 |
| PYREXIA<br>subjects affected / exposed<br>occurrences (all)                 | 6 / 91 (6.59%)<br>6    | 1 / 46 (2.17%)<br>1 | 3 / 84 (3.57%)<br>3 |
| Gastrointestinal disorders  |                        |                     |                     |
| NAUSEA<br>subjects affected / exposed<br>occurrences (all)                  | 2 / 91 (2.20%)<br>2    | 2 / 46 (4.35%)<br>2 | 1 / 84 (1.19%)<br>1 |
| DIARRHOEA<br>subjects affected / exposed<br>occurrences (all)               | 3 / 91 (3.30%)<br>4    | 0 / 46 (0.00%)<br>0 | 2 / 84 (2.38%)<br>2 |
| Skin and subcutaneous tissue disorders                                      |                        |                     |                     |
| RASH<br>subjects affected / exposed<br>occurrences (all)                    | 4 / 91 (4.40%)<br>4    | 3 / 46 (6.52%)<br>3 | 3 / 84 (3.57%)<br>3 |
| Musculoskeletal and connective tissue disorders                             |                        |                     |                     |
| ARTHRALGIA<br>subjects affected / exposed<br>occurrences (all)              | 6 / 91 (6.59%)<br>8    | 1 / 46 (2.17%)<br>1 | 1 / 84 (1.19%)<br>1 |
| BACK PAIN<br>subjects affected / exposed<br>occurrences (all)               | 3 / 91 (3.30%)<br>3    | 0 / 46 (0.00%)<br>0 | 3 / 84 (3.57%)<br>3 |
| RHEUMATOID ARTHRITIS<br>subjects affected / exposed<br>occurrences (all)    | 10 / 91 (10.99%)<br>12 | 4 / 46 (8.70%)<br>6 | 5 / 84 (5.95%)<br>5 |
| Infections and infestations   |                        |                     |                     |
| BRONCHITIS<br>subjects affected / exposed<br>occurrences (all)              | 6 / 91 (6.59%)<br>6    | 0 / 46 (0.00%)<br>0 | 2 / 84 (2.38%)<br>2 |
| COVID-19  |                        |                     |                     |

|  |                        |                       |                        |
|--|------------------------|-----------------------|------------------------|
| subjects affected / exposed<br>occurrences (all) | 15 / 91 (16.48%)<br>17 | 8 / 46 (17.39%)<br>8  | 17 / 84 (20.24%)<br>18 |
| INFLUENZA  |                        |                       |                        |
| subjects affected / exposed<br>occurrences (all) | 1 / 91 (1.10%)<br>1    | 1 / 46 (2.17%)<br>1   | 3 / 84 (3.57%)<br>3    |
| NASOPHARYNGITIS                                  |                        |                       |                        |
| subjects affected / exposed<br>occurrences (all) | 9 / 91 (9.89%)<br>11   | 4 / 46 (8.70%)<br>4   | 6 / 84 (7.14%)<br>6    |
| PHARYNGITIS                                      |                        |                       |                        |
| subjects affected / exposed<br>occurrences (all) | 5 / 91 (5.49%)<br>6    | 0 / 46 (0.00%)<br>0   | 3 / 84 (3.57%)<br>3    |
| UPPER RESPIRATORY TRACT<br>INFECTION             |                        |                       |                        |
| subjects affected / exposed<br>occurrences (all) | 6 / 91 (6.59%)<br>6    | 5 / 46 (10.87%)<br>5  | 12 / 84 (14.29%)<br>13 |
| URINARY TRACT INFECTION                          |                        |                       |                        |
| subjects affected / exposed<br>occurrences (all) | 3 / 91 (3.30%)<br>3    | 5 / 46 (10.87%)<br>10 | 8 / 84 (9.52%)<br>10   |

| <b>Non-serious adverse events</b>                        | Period 2 (Extension<br>Period) ABBV-154<br>150 mg EOW | Period 2 (Extension<br>Period) ABBV-154<br>340 mg E4W |  |
|--|---|---|--|
| Total subjects affected by non-serious<br>adverse events |   |   |  |
| subjects affected / exposed                              | 56 / 86 (65.12%)                                      | 47 / 89 (52.81%)                                      |  |
| Injury, poisoning and procedural<br>complications        |   |   |  |
| CONTUSION  |   |   |  |
| subjects affected / exposed<br>occurrences (all)         | 5 / 86 (5.81%)<br>5                                   | 1 / 89 (1.12%)<br>1                                   |  |
| FALL   |   |   |  |
| subjects affected / exposed<br>occurrences (all)         | 2 / 86 (2.33%)<br>2                                   | 0 / 89 (0.00%)<br>0                                   |  |
| Vascular disorders                                       |   |   |  |
| HYPERTENSION   |   |   |  |
| subjects affected / exposed<br>occurrences (all)         | 3 / 86 (3.49%)<br>3                                   | 5 / 89 (5.62%)<br>5                                   |  |
| Nervous system disorders                                 |   |   |  |
| HEADACHE   |   |   |  |

|  |                      |                     |  |
|--|----------------------|---------------------|--|
| subjects affected / exposed<br>occurrences (all)   | 5 / 86 (5.81%)<br>5  | 1 / 89 (1.12%)<br>1 |  |
| General disorders and administration<br>site conditions<br>INJECTION SITE DISCOLOURATION<br>subjects affected / exposed<br>occurrences (all) | 5 / 86 (5.81%)<br>5  | 3 / 89 (3.37%)<br>3 |  |
| INJECTION SITE BRUISING<br>subjects affected / exposed<br>occurrences (all)  | 2 / 86 (2.33%)<br>4  | 6 / 89 (6.74%)<br>6 |  |
| INJECTION SITE ERYTHEMA<br>subjects affected / exposed<br>occurrences (all)  | 3 / 86 (3.49%)<br>14 | 5 / 89 (5.62%)<br>8 |  |
| OEDEMA PERIPHERAL<br>subjects affected / exposed<br>occurrences (all)  | 3 / 86 (3.49%)<br>3  | 0 / 89 (0.00%)<br>0 |  |
| PYREXIA<br>subjects affected / exposed<br>occurrences (all)  | 3 / 86 (3.49%)<br>3  | 0 / 89 (0.00%)<br>0 |  |
| Gastrointestinal disorders<br>NAUSEA<br>subjects affected / exposed<br>occurrences (all)   | 5 / 86 (5.81%)<br>7  | 2 / 89 (2.25%)<br>2 |  |
| DIARRHOEA<br>subjects affected / exposed<br>occurrences (all)  | 5 / 86 (5.81%)<br>6  | 2 / 89 (2.25%)<br>2 |  |
| Skin and subcutaneous tissue disorders<br>RASH<br>subjects affected / exposed<br>occurrences (all)   | 4 / 86 (4.65%)<br>9  | 0 / 89 (0.00%)<br>0 |  |
| Musculoskeletal and connective tissue<br>disorders<br>ARTHRALGIA<br>subjects affected / exposed<br>occurrences (all)                         | 3 / 86 (3.49%)<br>3  | 1 / 89 (1.12%)<br>1 |  |
| BACK PAIN<br>subjects affected / exposed<br>occurrences (all)  | 8 / 86 (9.30%)<br>8  | 2 / 89 (2.25%)<br>2 |  |



|  |                        |                        |  |
|--|------------------------|------------------------|--|
| RHEUMATOID ARTHRITIS<br>subjects affected / exposed<br>occurrences (all)                 | 11 / 86 (12.79%)<br>14 | 8 / 89 (8.99%)<br>10   |  |
| Infections and infestations  |                        |                        |  |
| BRONCHITIS<br>subjects affected / exposed<br>occurrences (all)                           | 2 / 86 (2.33%)<br>2    | 6 / 89 (6.74%)<br>6    |  |
| COVID-19<br>subjects affected / exposed<br>occurrences (all)                             | 15 / 86 (17.44%)<br>16 | 16 / 89 (17.98%)<br>17 |  |
| INFLUENZA<br>subjects affected / exposed<br>occurrences (all)                            | 3 / 86 (3.49%)<br>3    | 4 / 89 (4.49%)<br>6    |  |
| NASOPHARYNGITIS<br>subjects affected / exposed<br>occurrences (all)                      | 11 / 86 (12.79%)<br>13 | 11 / 89 (12.36%)<br>15 |  |
| PHARYNGITIS<br>subjects affected / exposed<br>occurrences (all)                          | 3 / 86 (3.49%)<br>3    | 1 / 89 (1.12%)<br>1    |  |
| UPPER RESPIRATORY TRACT<br>INFECTION<br>subjects affected / exposed<br>occurrences (all) | 8 / 86 (9.30%)<br>10   | 7 / 89 (7.87%)<br>7    |  |
| URINARY TRACT INFECTION<br>subjects affected / exposed<br>occurrences (all)              | 6 / 86 (6.98%)<br>8    | 5 / 89 (5.62%)<br>5    |  |

**More information**

**Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? Yes

| Date          | Amendment   |
|---------------|---|
| 12 April 2022 | <p>Protocol Version 2.0</p> <p>Typographical corrections or edits were made for consistency. In addition, updates and clarifications were made to study procedures, including but not limited to the following:</p> <ul style="list-style-type: none"><li>• Added a 104-week LTE Period 2 and renamed the originally planned double-blind LTE period "Double-Blind, Long-term Extension Period 1"</li><li>• Updated wording to clarify when unblinding would occur</li><li>• Updated/clarified eligibility criteria related to b/tsDMARDs</li><li>• Changed the definition of ITT population from all randomized subjects to all subjects who were randomized and received at least 1 dose of study drug</li><li>• Updates/clarifications to Objectives, Hypotheses, and Estimands</li><li>• The Optional Synovial Biopsy Substudy was removed as it was determined it will not be possible to enroll enough subjects into the Substudy to achieve scientific goals</li><li>• Added 70-Day Follow-up Period to the description of the overall study design</li><li>• Clarified primary and final analysis timing</li><li>• Clarified that subjects previously on placebo will be re-randomized</li><li>• Updates/clarifications made to the section on requirements for contraception, breastfeeding, and pregnancy</li></ul> |

Notes:

**Interruptions (globally)**

Were there any global interruptions to the trial? No

**Limitations and caveats**

None reported